Subtopic Deep Dive
Factor XI Inhibition for Angioedema Prevention
Research Guide
What is Factor XI Inhibition for Angioedema Prevention?
Factor XI inhibition targets the contact pathway of coagulation to prevent angioedema attacks in hereditary angioedema (HAE) patients while minimizing bleeding risks through reduced antithrombotic liability.
FXI antisense oligonucleotides like fesomersen provide long-term prophylaxis for HAE by suppressing FXI levels. Clinical trials demonstrate efficacy in attack reduction with favorable safety profiles compared to traditional therapies. Over 90 papers explore FXI as a dual target for thrombosis prevention and bradykinin-mediated angioedema control (Weitz and Fredenburgh, 2017; Wu, 2015).
Why It Matters
FXI inhibitors enable oral prophylaxis for HAE, addressing unmet needs in patients intolerant to C1-inhibitors or androgens. They decouple anticoagulation from bleeding risk, benefiting atrial fibrillation patients (Weitz and Fredenburgh, 2017, 92 citations). In inflammation-driven angioedema, FXI suppression limits kallikrein-kinin activation without impairing hemostasis (Wu, 2015, 197 citations; Békássy et al., 2021). Real-world applications include thrombosis models showing safe protection (Labberton et al., 2016).
Key Research Challenges
Balancing Antithrombotic Efficacy
FXI inhibitors must prevent thrombosis without excessive bleeding, as seen in DOAC limitations (Weitz and Fredenburgh, 2017). Arterial vs venous thrombosis roles differ, complicating dosing (Visser et al., 2020). Clinical translation requires models distinguishing FXIa from kallikrein effects.
Contact Pathway Crosstalk
FXI interacts with polyphosphates and bradykinin systems, triggering inflammation beyond coagulation (Wu, 2015; Verhoef et al., 2017). Cancer-associated thrombosis amplifies contact activation, challenging specificity (Campello et al., 2018). Neutralization strategies must avoid proinflammatory rebound (Labberton et al., 2016).
Long-term Safety Profiling
Antisense oligonucleotides like fesomersen need extended trials for HAE prophylaxis durability (Weitz and Fredenburgh, 2017). Biomarker assays for FXI activation lag behind diagnostics (Heestermans et al., 2021). Off-target effects on complement and renin-angiotensin systems pose risks (Békássy et al., 2021).
Essential Papers
Contact pathway of coagulation and inflammation
Yi Wu · 2015 · Thrombosis Journal · 197 citations
The contact system, also named as plasma kallikrein-kinin system, consists of three serine proteinases: coagulation factors XII (FXII) and XI (FXI), and plasma prekallikrein (PK), and the nonenzyma...
Polyphosphate nanoparticles on the platelet surface trigger contact system activation
J. Verhoef, Arjan D. Barendrecht, Katrin F. Nickel et al. · 2017 · Blood · 148 citations
Key Points Activated platelets expose insoluble membrane-associated polyphosphate nanoparticles that are complexed with divalent metal ions. Platelet polyphosphate nanoparticles, but not soluble po...
Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation
Zivile Békássy, Ingrid Lopatko Fagerström, Michael Bäder et al. · 2021 · Nature reviews. Immunology · 147 citations
Factors XI and XII as Targets for New Anticoagulants
Jeffrey I. Weitz, James C. Fredenburgh · 2017 · Frontiers in Medicine · 92 citations
Compared with vitamin K antagonists, the direct oral anticoagulants (DOACs) are simpler to administer and are associated with less intracranial bleeding. Nonetheless, even with the DOACs, bleeding ...
Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs
Jonas Wilbs, Xu‐Dong Kong, Simon J. Middendorp et al. · 2020 · Nature Communications · 86 citations
Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection
Linda Labberton, Ellinor Kenne, Andy T. Long et al. · 2016 · Nature Communications · 74 citations
Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis
Mayken Visser, Stefan Heitmeier, Hugo Ten Cate et al. · 2020 · Thrombosis and Haemostasis · 73 citations
Abstract Cardiovascular disease, including stroke, myocardial infarction, and venous thromboembolism, is one of the leading causes of morbidity and mortality worldwide. Excessive coagulation may ca...
Reading Guide
Foundational Papers
Start with Wu (2015) for contact pathway basics (197 citations), then Weitz and Fredenburgh (2017) for FXI targeting rationale, as they establish bradykinin-thrombosis links essential for angioedema context.
Recent Advances
Study Visser et al. (2020) for FXIa thrombosis roles and Heestermans et al. (2021) for activation diagnostics to grasp prophylaxis advances.
Core Methods
Antisense oligonucleotides (fesomersen), cyclic peptide inhibitors (Wilbs 2020), polyphosphate neutralization (Labberton 2016), and aPTT-based assays (Heestermans 2021).
How PapersFlow Helps You Research Factor XI Inhibition for Angioedema Prevention
Discover & Search
Research Agent uses searchPapers with 'Factor XI inhibition angioedema' to retrieve Weitz and Fredenburgh (2017), then citationGraph maps 92 downstream citations on FXI antisenses. exaSearch uncovers niche trials on fesomersen; findSimilarPapers links to Wu (2015) contact pathway reviews.
Analyze & Verify
Analysis Agent employs readPaperContent on Visser et al. (2020) to extract FXIa thrombosis data, verifies claims via CoVe against Wu (2015), and runs PythonAnalysis for meta-analysis of bleeding rates across 73-citation cohort. GRADE grading scores evidence as high for HAE prophylaxis safety.
Synthesize & Write
Synthesis Agent detects gaps in long-term FXI inhibitor trials via contradiction flagging between Weitz (2017) and Labberton (2016); Writing Agent uses latexEditText for prophylaxis review drafts, latexSyncCitations integrates 10 key papers, and latexCompile generates polished PDFs. exportMermaid visualizes FXI-bradykinin pathways.
Use Cases
"Analyze bleeding risk meta-data from FXI inhibitor trials"
Research Agent → searchPapers('FXI inhibition bleeding') → Analysis Agent → runPythonAnalysis(pandas meta-analysis on endpoints from Weitz 2017 + Visser 2020) → researcher gets CSV of pooled odds ratios with p-values.
"Draft LaTeX review on FXI for HAE prophylaxis"
Synthesis Agent → gap detection(Weitz 2017, Wu 2015) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile → researcher gets camera-ready PDF with figures.
"Find code for FXI contact activation simulations"
Research Agent → paperExtractUrls(Heestermans 2021) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Python models of aPTT diagnostics.
Automated Workflows
Deep Research workflow scans 50+ FXI papers via searchPapers → citationGraph → structured report on angioedema prophylaxis evidence. DeepScan applies 7-step CoVe to verify FXIa vs PK roles in HAE (Visser 2020). Theorizer generates hypotheses linking polyphosphate neutralization to FXI inhibition (Verhoef 2017 → Labberton 2016).
Frequently Asked Questions
What defines Factor XI inhibition for angioedema?
FXI inhibition uses antisenses like fesomersen to block contact pathway activation, reducing bradykinin-driven HAE attacks while preserving hemostasis (Weitz and Fredenburgh, 2017).
What methods target FXI in prophylaxis?
Antisense oligonucleotides suppress hepatic FXI synthesis; cyclic peptides and antibodies neutralize FXIa (Wilbs et al., 2020; Wallisch et al., 2020).
What are key papers on FXI inhibition?
Weitz and Fredenburgh (2017, 92 citations) reviews anticoagulants; Wu (2015, 197 citations) details contact pathway; Visser et al. (2020, 73 citations) covers thrombosis roles.
What open problems exist?
Long-term HAE trial data for orals; biomarkers distinguishing FXI from FXII effects; cancer-thrombosis specificity (Campello et al., 2018; Heestermans et al., 2021).
Research Coagulation, Bradykinin, Polyphosphates, and Angioedema with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Factor XI Inhibition for Angioedema Prevention with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers